Congrats to PanCAN on the great results in advanced #PancreaticCancer Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial thelancet.com/journals/lanon…

New research reveals #PancreaticCancer patients who receive precision medicine live an average of one year longer than those who do not. Mike Pishvaian Perthera PanCAN bit.ly/39wvir3

Genetically targeted therapy significantly extended survival for patients with pancreatic cancer compared with standard chemo, according to study in The Lancet Oncology let by Michael Pishvaian MD Mike Pishvaian Johns Hopkins Kimmel Cancer Center bit.ly/38nZOlp #PrecisionMedicine

Thanks to Mike Pishvaian and PanCAN and KYT program!

.PanCAN’s chief science officer, Lynn Matrisian, sits down with Let's Win Pancreatic Cancer 💜 to discuss the exciting study published in The Lancet Oncology earlier this year on molecular profiling for #pancreaticcancer patients. letswinpc.org/promising-scie…

Our #CGP analysis Dr. Andrew Hendifar of #KRAS variants and their prognostic/predictive implications in #pancsm including poorly described #KRASQ61 #KRASWT tumors also w/actionable targets poster tomorrow 5/29/20 collab w/Perthera PanCAN @CSCancerCare meetinglibrary.asco.org/record/186397/…

Dear Colleagues at #ASCO20 A great pleasure to present OUR TOP #OncoAlert 🚨abstracts as picked by our expert colleague Mike Pishvaian Hope they help everyone navigate the meeting in terms of #GI #Cancers #CRCSM #colorectalcancer #Cholangiocarcinoma Best Gil Morgan, MD

Check out our ASCO poster on #KRAS variants in pancreatic cancer using #RealWorldEvidence from the Perthera platform for #PrecisionOncology; exploring KRAS Q61 as a novel biomarker for shorter PFS on FOLFIRINOX with Dr. Andrew Hendifar Mike Pishvaian et al perthera.com/asco20/

Our #ASCO20 #RealWorldEvidence poster on #KRAS variants in pancreatic cancer is now online! Novel association between KRAS Q61 & shorter PFS on FOLFIRINOX being explored with Dr. Andrew Hendifar Mike Pishvaian #pancsm perthera.com/asco20/

#PrecisionMedicine 🚨 in #pancreaticcancer PanCAN Lustgarten Foundation The NC Pancreas Foundation Lead Mike Pishvaian and Andrew Hendifar through Academic & Community Cancer Research United Mayo Clinic Comprehensive Cancer Center Binimetinib & Encorafenib in Pancreatic Cancer in tumors With a Somatic #BRAFV600E Mutation clinicaltrials.gov/ct2/show/NCT04…

We're excited to announce a paper published today in @ASCO_Pubs #JCOPO that looks at the outcomes of #pancreaticcancer patients with alterations to the RAF gene and treatment targeted to that genetic alteration. Learn more at pcan.at/3x729b

ASCO Publications Amazing collaboration w/ Dr. Andrew Hendifar @CSCancerCare Ed NFkB Mike Pishvaian Perthera Dana-Farber Vivek Subbiah, MD Kenna Shaw MD Anderson Cancer Center UCSF Helen Diller Family Comprehensive Cancer Ctr Eileen M O’Reilly @sloan_kettering George Mason University Test Account Johns Hopkins Kimmel Cancer Center Emily McLaughlin PanCAN

"Because the alterations are so rare, 1 single institution wouldn’t be able to draw conclusions about the best treatment approaches" Emily McLaughlin PanCAN - wonderful example of collaboration for the benefit of #pancreaticcancer patients! 💜

🚨Hot off the press 👉Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes. Kudos to PanCAN team Emily McLaughlin Allison Rosenzweig Dr. Andrew Hendifar Mike Pishvaian Kenna Shaw et al for the collaboration & perseverance ASCO Publications bit.ly/3kvNg3E

It was?? That's AWESOME‼️😃🎉 🙏so much Debyani Chakravarty, PhD 🇺🇦 for 👉this Huge CONGRATS for SUCH a TEAM🏅effort Dr. Andrew Hendifar Ed NFkB Perthera Brian Wolpin Vivek Subbiah, MD Erik Collisson Isha Singh Tim Cannon Kenna Shaw Chip Petricoin Sam Klempner Emily McLaughlin Andrea Wang-gillam Eileen M O’Reilly

📢In preparation for #ASCO22, I wanted to present my list for the #PancreaticCancer abstracts to👀for ASCO Again,🙏note - I went through a LOT of abstracts, and I definitely may have missed some‼️ 👉And these are not in any particular order ✅But enjoy, RT, and reply😀

Dr Thomas Seufferlein of Uniklinik Ulm shows promising data that there could be hidden subpopulations that when matched with targeted therapy may impact treatment outcomes in #pancsm #GIonc #ASCO22

Great to see a shoutout to our Perthera PanCAN paper in LancetOncology led by Mike Pishvaian at #asco22 during the Friday "Can We Begin to Predict Responders to Targeted Therapy in Gastrointestinal Cancer?" Session! pubmed.ncbi.nlm.nih.gov/32135080/

I'm expecting this to be a more exciting Jedi/padawan showdown than this week's obi-wan episode #pancsm #ASCO22 #medwitter Mike Pishvaian John Marshall

.Yeh Lab presenting PanCAN Know Your Tumor data from Mike Pishvaian showing survival benefit of #pancreaticcancer patients receiving #precisionmedicine matched therapy. #AACRpan22